Supreme Court rules on fight between drugmakers in "skinny label" patent case

Chronological Source Flow
Back

AI Fusion Summary

The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin patents regarding skinny labels. This decision overturns a lower court ruling, reducing the legal vulnerability of generic drugmakers producing lower-cost prescription medicines.
Community Comments
Loading updates...
0